{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to the small number of events.","groupId":"OG000","lowerLimit":"28.7","upperLimit":"NA","value":"42.1"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"39.5","value":"27.6"},{"comment":"Not estimable due to the small number of events.","groupId":"OG002","lowerLimit":"30.3","upperLimit":"NA","value":"37.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"74"}],"units":"Participants"}],"description":"DOR is defined as the time frame for participants who achieve an overall response as the time from the first occurrence of response (CR or PR according to the Revised Response Criteria for Malignant Lymphoma \\[Cheson 2014\\]) to disease progression or death, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg) for approximately 104 weeks, followed by ibrutinib monotherapy until disease progression (PD), unacceptable toxicity or withdrawal of consent. Venetoclax was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG000","title":"Randomization Phase: Ibrutinb + Venetoclax"},{"description":"Participants were randomized to ibrutinib 560 mg and placebo for approximately 104 weeks, followed by ibrutinib monotherapy until PD, unacceptable toxicity or withdrawal of consent. Placebo was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG001","title":"Randomization Phase: Ibrutinib + Placebo"},{"description":"Participants were treated withibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg).","id":"OG002","title":"Treatment-naive Open-label Arm"}],"paramType":"MEDIAN","populationDescription":"All randomized participants and all enrolled treatment-naïve participants achieving response (partial response or better)","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)","title":"Duration of Response (DOR) (Randomization Phase and Treatment-Naive Arm)","type":"SECONDARY","unitOfMeasure":"months"}